1:51 PM
 | 
Dec 21, 2017
 |  BC Innovations  |  Emerging Company Profile

Neoantigens for all

How Nouscom is creating personalized and off-the-shelf neoantigen vaccines

Nouscom AG has a simplified neoantigen platform that cuts production time, designed to deliver vaccines to cancer patients more quickly than the standard methods. With a two-pronged approach, the company is developing both personalized vaccines and off-the-shelf ones that could become first in class.

Nouscom’s platform is unique in using replication-deficient Great Apes Adenovirus vectors as a prime and Modified Vaccinia Virus Ankara vectors as a boost, each of which encodes up to 100 neoantigens.

According to co-founder and CEO Alfredo Nicosia, a key benefit is that the platform is based on vectors developed by the company’s founders while at Okairos AG. Those vectors were tested in infectious diseases in over 4,000 healthy volunteers, and induced “a very strong CD8+ T cell response,” he said.Okairos was acquired by GlaxoSmithKline plc in 2013.

Nouscom has developed two...

Read the full 664 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >